Charles Schwab Investment Management Inc. Buys 10,542 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Charles Schwab Investment Management Inc. boosted its position in Kura Oncology, Inc. (NASDAQ:KURA) by 1.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 635,494 shares of the company’s stock after buying an additional 10,542 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.82% of Kura Oncology worth $5,535,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after acquiring an additional 1,750 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Kura Oncology by 2.0% in the 4th quarter. Rhumbline Advisers now owns 99,991 shares of the company’s stock worth $871,000 after acquiring an additional 1,923 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after acquiring an additional 2,076 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares in the last quarter. Finally, Bellevue Group AG boosted its holdings in Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after purchasing an additional 3,600 shares during the last quarter.

Kura Oncology Stock Down 6.9 %

Shares of NASDAQ KURA opened at $7.12 on Wednesday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $574.98 million, a P/E ratio of -3.02 and a beta of 0.85. Kura Oncology, Inc. has a 52 week low of $6.79 and a 52 week high of $23.48. The business has a 50-day simple moving average of $7.83 and a two-hundred day simple moving average of $12.21.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. Research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 over the last three months. 5.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. UBS Group dropped their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Scotiabank cut their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. JMP Securities reaffirmed a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.